Harrow Health Inc (HROW)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Harrow Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 39.10 $ — 39% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 33.7%
- Exp. sales growth 3Y > 5% 37.9%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 37.9%
- Net debt < 4x EBIT 4.6x
- EBIT positive, 10Y straight 6
- Max. EBIT decline < 50% 77.6%
- Return on equity > 15% –
- ROCE > 15% 12.7%
- Expected return > 10% 41.9%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 45.4% passed
- More than 10% revenue growth is expected for the coming year 48.0% passed
- Share count grows by less than 3% a year 10.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 52.1% passed
- Gross margin at 40% or higher and without meaningful erosion 75.1% passed
- Goodwill from acquisitions does not grow faster than revenue 0.1% passed
- Net debt below twice EBITDA 4.3 x EBITDA failed
- Operating cash flow covers the profits of the last three years 73 m passed
- Return on capital at 15% or higher, or up versus two years ago 12.7% passed
- Insiders hold at least 10% or are net buyers 15.5% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 73.3% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.45 | 0.24 – 0.56 | 349 | – | 3 |
| 12/31/2027 | 2.68 | 2.16 – 3.02 | 518 | 499.3% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.23 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.19 | – | 67 | 83.80 | 10.10 | -18 | -55 |
| 2025: Q1 | -0.50 | – | 48 | 38.30 | -37.20 | 20 | 20 |
| 2025: Q2 | 0.13 | – | 64 | 30.20 | 7.80 | -1 | -1 |
| 2025: Q3 | 0.03 | – | 72 | 45.40 | 1.40 | 17 | 16 |
| 2025: Q4 | 0.18 | -4.80 | 89 | 33.30 | 7.40 | 8 | 8 |
| 2026: Q1 | -0.74 | – | 44 | -7.60 | -62.40 | -9 | -9 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 20 | -16 | -19 | -1.50 | -11 | 6 | 27 |
| 2017 | 27 | -12 | -12 | -0.60 | -9 | 3 | 24 |
| 2018 | 41 | -5 | 15 | 0.61 | 1 | 25 | 49 |
| 2019 | 51 | -5 | 0 | 0.01 | 1 | 28 | 59 |
| 2020 | 49 | 0 | -3 | -0.13 | -1 | 27 | 57 |
| 2021 | 72 | 2 | -18 | -0.67 | 5 | 11 | 98 |
| 2022 | 89 | 2 | -14 | -0.51 | 2 | 27 | 157 |
| 2023 | 130 | 0 | -24 | -0.75 | 4 | 70 | 312 |
| 2024 | 200 | 9 | -17 | -0.49 | -22 | 70 | 389 |
| 2025 | 272 | 39 | -5 | -0.14 | 44 | 52 | 399 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Harrow, Inc., ein Augenheilkunde-Pharmaunternehmen, beschäftigt sich mit der Entdeckung, Entwicklung und Vermarktung ophthalmologischer Pharmaprodukte in den USA.
| Employees | 373 |
|---|---|
| Headquarters | Nashville, TN |
| Address | 1A Burton Hills Boulevard, 37215 Nashville, United States |
| Phone | 615 733 4730 |
| Website | harrow.com |
| IPO Date | 28. Sep 2007 |
| ISIN | US4158581094 |
| Stock Split | 1:5 on 02/08/2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark L. Baum J.D. | CEO, Chairman of the Board & Founder | 1972 |
| Andrew R. Boll C.F.A., C.M.A. | President, CFO & Corporate Secretary | 1982 |
| Amir W. Shojaei Ph.D., Pharm.D. | Chief Scientific Officer | 1968 |
| Francis W. Mullery | President & CEO of Harrow's ImprimisRx Division | – |
| Randall E. Pollard | Chief Accounting Officer | 1972 |
| Michael D. Biega | Vice President of Investor Relations & Communications | – |
| Brett A. Burrell | Vice President of Legal & Compliance | – |
| Kim Barratt | Chief Talent Officer | – |
| Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs & Pharmacovigilance | – |
| Prashanth S. Annavajjhala | Chief of Staff | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.